IPO
Promore Pharma AB held Extraordinary Shareholder’s Meeting on Tuesday, 22 October 2019.
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management
Companies have raised over 6x more investment thanks to grant funding
Corteva Agriscience announced a $500,000 commitment to create the Corteva Agriscience Climate Positive Challenge to catalyze a movement toward climate-positive agriculture.
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomics data and artificial intelligence, announced its financial results for first-half 2019.
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
PRESS RELEASES